Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 6/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13496274 | 0.84 | ERAP2 (0.54) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL29194171 | 0.82 | GSR (0.50) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL2734207 | 0.81 | ERAP2 (0.52) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL3485077 | 0.78 | DPP7 (0.58) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL6844633 | 0.78 | DPP8 (0.46) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL22769258 | 0.78 | DPP8 (0.43) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL14453693 | 0.77 | DPP7 (0.54) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL7747523 | 0.77 | DPP7 (0.58) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL503847 | 0.77 | DPP7 (0.58) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL21027659 | 0.77 | DPP8 (0.50) | DPP8DPP9DPP7GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846893-B2 | Non-ionically bound constructs, and compositions and kits comprising domains | ENZO BIOCHEM, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8742090-B2 | Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses | ENZO BIOCHEM, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8735145-B2 | Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses | ENZO BIOCHEM, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2042606-A1 | Novel property effecting and/or property exhibiting compositions for therapeutic and diagnostic use | ENZO THERAPEUTICS, INC. (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080248564-A1 | Expression vector comprising ligand conjugates for use and expression of heterologus nucleotide sequences in cells | ENZO THERAPEUTICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| EP-0779365-B1 | Methods to introduce nucleic acid into cells for therapeutic and diagnostic uses | ENZO THERAPEUTICS INC (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20080108139-A1 | Expression vector comprising nucleotide sequences coding polymerase for use in eukaryotic specific expression of functional heterologous proteins | ENZO THERAPEUTICS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20030104620-A1 | Expression vector for expression of heterologous polypeptides and amplification of cell viral resistance; viricides | ENZO BIOCHEM, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030087434-A1 | Expression vector for use gene transfer tool in genetic engineering | ENZO BIOCHEM, INC. | 2003-05-08 | — | — | US | disclosed |
| US-20010007767-A1 | Genetic engineering | ENZO BIOCHEM, INC. | 2001-07-12 | — | — | US | disclosed |
| US-20010006816-A1 | Dna, rna hybrid | ENZO BIOCHEM, INC. | 2001-07-05 | — | — | US | disclosed |
| US-20010006815-A1 | Chemical modification | ENZO BIOCHEM, INC. | 2001-07-05 | — | — | US | disclosed |
| US-20010006814-A1 | Chemical modification | ENZO BIOCHEM, INC. | 2001-07-05 | — | — | US | disclosed |
| EP-0779365-A2 | Methods to introduce nucleic acid into cells for therapeutic and diagnostic uses | ENZO THERAPEUTICS, INC. (US) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030104620-A1 | Expression vector for expression of heterologous polypeptides and amplification of cell viral resistance; viricides | HAVCR2, RNASE1, RNPEP | DPP8 747/4885DPP9 605/4885DPP7 563/4885 |
| US-20010006814-A1 | Chemical modification | RNASE1, DNASE1L3, DNASE1 | DPP8 1009/4885DPP9 838/4885DPP7 1131/4885 |
| US-20080108139-A1 | Expression vector comprising nucleotide sequences coding polymerase for use in eukaryotic specific expression of functional heterologous proteins | RNGTT, RNASE1, MRPL21 | DPP8 2487/4885DPP9 2695/4885DPP7 2107/4885 |
| US-20030087434-A1 | Expression vector for use gene transfer tool in genetic engineering | RNASE1, GUSB, DCLRE1B | DPP8 2540/4885DPP9 1965/4885DPP7 2015/4885 |
| US-20010007767-A1 | Genetic engineering | DCLRE1B, RNASE1, DNASE1L3 | DPP8 2048/4885DPP9 1789/4885DPP7 2070/4885 |
| US-20010006815-A1 | Chemical modification | RNASE1, DNASE1L3, DNASE1 | DPP8 1009/4885DPP9 838/4885DPP7 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.